FDA
- Status: approved
Influenza (Influenza and COVID-19 Combination B) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
BioNTech is the originator. The local marketing authorisation holder may differ — check the official source linked above.
annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.